ESCMID*  ||| S:0 E:8 ||| NNP
guideline  ||| S:8 E:18 ||| NN
for  ||| S:18 E:22 ||| IN
the  ||| S:22 E:26 ||| DT
diagnosis  ||| S:26 E:36 ||| NN
and  ||| S:36 E:40 ||| CC
management  ||| S:40 E:51 ||| NN
of  ||| S:51 E:54 ||| IN
Candida  ||| S:54 E:62 ||| NNP
diseases  ||| S:62 E:71 ||| VBD
2012 ||| S:71 E:75 ||| CD
:  ||| S:75 E:77 ||| :
non-neutropenic  ||| S:77 E:93 ||| JJ
adult  ||| S:93 E:99 ||| NN
patients  ||| S:99 E:108 ||| NNS
This  ||| S:108 E:113 ||| DT
part  ||| S:113 E:118 ||| NN
of  ||| S:118 E:121 ||| IN
the  ||| S:121 E:125 ||| DT
EFISG  ||| S:125 E:131 ||| NNP
guidelines  ||| S:131 E:142 ||| NNS
focuses  ||| S:142 E:150 ||| VBZ
on  ||| S:150 E:153 ||| IN
non-neutropenic  ||| S:153 E:169 ||| JJ
adult  ||| S:169 E:175 ||| NN
patients ||| S:175 E:183 ||| NNS
.  ||| S:183 E:185 ||| .
Only  ||| S:185 E:190 ||| RB
a  ||| S:190 E:192 ||| DT
few  ||| S:192 E:196 ||| JJ
of  ||| S:196 E:199 ||| IN
the  ||| S:199 E:203 ||| DT
numerous  ||| S:203 E:212 ||| JJ
recommendations  ||| S:212 E:228 ||| NNS
can  ||| S:228 E:232 ||| MD
be  ||| S:232 E:235 ||| VB
summarized  ||| S:235 E:246 ||| VBN
in  ||| S:246 E:249 ||| IN
the  ||| S:249 E:253 ||| DT
abstract ||| S:253 E:261 ||| NN
.  ||| S:261 E:263 ||| .
Prophylactic  ||| S:263 E:276 ||| JJ
usage  ||| S:276 E:282 ||| NN
of  ||| S:282 E:285 ||| IN
fluconazole  ||| S:285 E:297 ||| NN
is  ||| S:297 E:300 ||| VBZ
supported  ||| S:300 E:310 ||| VBN
in  ||| S:310 E:313 ||| IN
patients  ||| S:313 E:322 ||| NNS
with  ||| S:322 E:327 ||| IN
recent  ||| S:327 E:334 ||| JJ
abdominal  ||| S:334 E:344 ||| JJ
surgery  ||| S:344 E:352 ||| NN
and  ||| S:352 E:356 ||| CC
recurrent  ||| S:356 E:366 ||| JJ
gastrointestinal  ||| S:366 E:383 ||| JJ
perforations  ||| S:383 E:396 ||| NN
or  ||| S:396 E:399 ||| CC
anastomotic  ||| S:399 E:411 ||| JJ
leakages ||| S:411 E:419 ||| NN
.  ||| S:419 E:421 ||| .
Candida  ||| S:421 E:429 ||| JJ
isolation  ||| S:429 E:439 ||| NN
from  ||| S:439 E:444 ||| IN
respiratory  ||| S:444 E:456 ||| JJ
secretions  ||| S:456 E:467 ||| NNS
alone  ||| S:467 E:473 ||| RB
should  ||| S:473 E:480 ||| MD
never  ||| S:480 E:486 ||| RB
prompt  ||| S:486 E:493 ||| JJ
treatment ||| S:493 E:502 ||| NN
.  ||| S:502 E:504 ||| .
For  ||| S:504 E:508 ||| IN
the  ||| S:508 E:512 ||| DT
targeted  ||| S:512 E:521 ||| JJ
initial  ||| S:521 E:529 ||| JJ
treatment  ||| S:529 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
candidaemia ||| S:542 E:553 ||| NN
,  ||| S:553 E:555 ||| ,
echinocandins  ||| S:555 E:569 ||| NNS
are  ||| S:569 E:573 ||| VBP
strongly  ||| S:573 E:582 ||| RB
recommended  ||| S:582 E:594 ||| VBN
while  ||| S:594 E:600 ||| IN
liposomal  ||| S:600 E:610 ||| JJ
amphotericin  ||| S:610 E:623 ||| JJ
B  ||| S:623 E:625 ||| NNP
and  ||| S:625 E:629 ||| CC
voriconazole  ||| S:629 E:642 ||| NNS
are  ||| S:642 E:646 ||| VBP
supported  ||| S:646 E:656 ||| VBN
with  ||| S:656 E:661 ||| IN
moderate ||| S:661 E:669 ||| JJ
,  ||| S:669 E:671 ||| ,
and  ||| S:671 E:675 ||| CC
fluconazole  ||| S:675 E:687 ||| NN
with  ||| S:687 E:692 ||| IN
marginal  ||| S:692 E:701 ||| JJ
strength ||| S:701 E:709 ||| NN
.  ||| S:709 E:711 ||| .
Treatment  ||| S:711 E:721 ||| NN
duration  ||| S:721 E:730 ||| NN
for  ||| S:730 E:734 ||| IN
candidaemia  ||| S:734 E:746 ||| NNS
should  ||| S:746 E:753 ||| MD
be  ||| S:753 E:756 ||| VB
a  ||| S:756 E:758 ||| DT
minimum  ||| S:758 E:766 ||| NN
of  ||| S:766 E:769 ||| IN
14  ||| S:769 E:772 ||| CD
days  ||| S:772 E:777 ||| NNS
after  ||| S:777 E:783 ||| IN
the  ||| S:783 E:787 ||| DT
end  ||| S:787 E:791 ||| NN
of  ||| S:791 E:794 ||| IN
candidaemia ||| S:794 E:805 ||| NN
,  ||| S:805 E:807 ||| ,
which  ||| S:807 E:813 ||| WDT
can  ||| S:813 E:817 ||| MD
be  ||| S:817 E:820 ||| VB
determined  ||| S:820 E:831 ||| VBN
by  ||| S:831 E:834 ||| IN
one  ||| S:834 E:838 ||| CD
blood  ||| S:838 E:844 ||| NN
culture  ||| S:844 E:852 ||| NN
per  ||| S:852 E:856 ||| IN
day  ||| S:856 E:860 ||| NN
until  ||| S:860 E:866 ||| IN
negativity ||| S:866 E:876 ||| NN
.  ||| S:876 E:878 ||| .
Switching  ||| S:878 E:888 ||| VBG
to  ||| S:888 E:891 ||| TO
oral  ||| S:891 E:896 ||| JJ
treatment  ||| S:896 E:906 ||| NN
after  ||| S:906 E:912 ||| IN
10  ||| S:912 E:915 ||| CD
days  ||| S:915 E:920 ||| NNS
of  ||| S:920 E:923 ||| IN
intravenous  ||| S:923 E:935 ||| JJ
therapy  ||| S:935 E:943 ||| NN
has  ||| S:943 E:947 ||| VBZ
been  ||| S:947 E:952 ||| VBN
safe  ||| S:952 E:957 ||| JJ
in  ||| S:957 E:960 ||| IN
stable  ||| S:960 E:967 ||| JJ
patients  ||| S:967 E:976 ||| NNS
with  ||| S:976 E:981 ||| IN
susceptible  ||| S:981 E:993 ||| JJ
Candida  ||| S:993 E:1001 ||| JJ
species ||| S:1001 E:1008 ||| NNS
.  ||| S:1008 E:1010 ||| .
In  ||| S:1010 E:1013 ||| IN
candidaemia ||| S:1013 E:1024 ||| NN
,  ||| S:1024 E:1026 ||| ,
removal  ||| S:1026 E:1034 ||| NN
of  ||| S:1034 E:1037 ||| IN
indwelling  ||| S:1037 E:1048 ||| JJ
catheters  ||| S:1048 E:1058 ||| NN
is  ||| S:1058 E:1061 ||| VBZ
strongly  ||| S:1061 E:1070 ||| RB
recommended ||| S:1070 E:1081 ||| VBN
.  ||| S:1081 E:1083 ||| .
If  ||| S:1083 E:1086 ||| IN
catheters  ||| S:1086 E:1096 ||| NNS
cannot  ||| S:1096 E:1103 ||| RB
be  ||| S:1103 E:1106 ||| VB
removed ||| S:1106 E:1113 ||| VBN
,  ||| S:1113 E:1115 ||| ,
lipid-based  ||| S:1115 E:1127 ||| JJ
amphotericin  ||| S:1127 E:1140 ||| JJ
B  ||| S:1140 E:1142 ||| NNP
or  ||| S:1142 E:1145 ||| CC
echinocandins  ||| S:1145 E:1159 ||| NNS
should  ||| S:1159 E:1166 ||| MD
be  ||| S:1166 E:1169 ||| VB
preferred  ||| S:1169 E:1179 ||| VBN
over  ||| S:1179 E:1184 ||| IN
azoles ||| S:1184 E:1190 ||| NN
.  ||| S:1190 E:1192 ||| .
Transoesophageal  ||| S:1192 E:1209 ||| JJ
echocardiography  ||| S:1209 E:1226 ||| NN
and  ||| S:1226 E:1230 ||| CC
fundoscopy  ||| S:1230 E:1241 ||| NNS
should  ||| S:1241 E:1248 ||| MD
be  ||| S:1248 E:1251 ||| VB
performed  ||| S:1251 E:1261 ||| VBN
to  ||| S:1261 E:1264 ||| TO
detect  ||| S:1264 E:1271 ||| VB
organ  ||| S:1271 E:1277 ||| JJ
involvement ||| S:1277 E:1288 ||| NN
.  ||| S:1288 E:1290 ||| .
Native  ||| S:1290 E:1297 ||| JJ
valve  ||| S:1297 E:1303 ||| JJ
endocarditis  ||| S:1303 E:1316 ||| NN
requires  ||| S:1316 E:1325 ||| VBZ
surgery  ||| S:1325 E:1333 ||| NN
within  ||| S:1333 E:1340 ||| IN
a  ||| S:1340 E:1342 ||| DT
week ||| S:1342 E:1346 ||| NN
,  ||| S:1346 E:1348 ||| ,
while  ||| S:1348 E:1354 ||| IN
in  ||| S:1354 E:1357 ||| IN
prosthetic  ||| S:1357 E:1368 ||| JJ
valve  ||| S:1368 E:1374 ||| JJ
endocarditis ||| S:1374 E:1386 ||| NN
,  ||| S:1386 E:1388 ||| ,
earlier  ||| S:1388 E:1396 ||| JJR
surgery  ||| S:1396 E:1404 ||| NN
may  ||| S:1404 E:1408 ||| MD
be  ||| S:1408 E:1411 ||| VB
beneficial ||| S:1411 E:1421 ||| JJ
.  ||| S:1421 E:1423 ||| .
The  ||| S:1423 E:1427 ||| DT
antifungal  ||| S:1427 E:1438 ||| JJ
regimen  ||| S:1438 E:1446 ||| NN
of  ||| S:1446 E:1449 ||| IN
choice  ||| S:1449 E:1456 ||| NN
is  ||| S:1456 E:1459 ||| VBZ
liposomal  ||| S:1459 E:1469 ||| JJ
amphotericin  ||| S:1469 E:1482 ||| JJ
B  ||| S:1482 E:1484 ||| NNP
+ ||| S:1484 E:1485 ||| NNP
/ ||| S:1485 E:1486 ||| NNP
-  ||| S:1486 E:1488 ||| :
flucytosine ||| S:1488 E:1499 ||| CD
.  ||| S:1499 E:1501 ||| .
In  ||| S:1501 E:1504 ||| IN
ocular  ||| S:1504 E:1511 ||| JJ
candidiasis ||| S:1511 E:1522 ||| NN
,  ||| S:1522 E:1524 ||| ,
liposomal  ||| S:1524 E:1534 ||| FW
amphotericin  ||| S:1534 E:1547 ||| FW
B  ||| S:1547 E:1549 ||| NNP
+ ||| S:1549 E:1550 ||| NNP
/ ||| S:1550 E:1551 ||| NNP
-  ||| S:1551 E:1553 ||| :
flucytosine  ||| S:1553 E:1565 ||| NN
is  ||| S:1565 E:1568 ||| VBZ
recommended  ||| S:1568 E:1580 ||| VBN
when  ||| S:1580 E:1585 ||| WRB
the  ||| S:1585 E:1589 ||| DT
susceptibility  ||| S:1589 E:1604 ||| NN
of  ||| S:1604 E:1607 ||| IN
the  ||| S:1607 E:1611 ||| DT
isolate  ||| S:1611 E:1619 ||| NN
is  ||| S:1619 E:1622 ||| VBZ
unknown ||| S:1622 E:1629 ||| JJ
,  ||| S:1629 E:1631 ||| ,
and  ||| S:1631 E:1635 ||| CC
in  ||| S:1635 E:1638 ||| IN
susceptible  ||| S:1638 E:1650 ||| JJ
isolates ||| S:1650 E:1658 ||| NN
,  ||| S:1658 E:1660 ||| ,
fluconazole  ||| S:1660 E:1672 ||| NN
and  ||| S:1672 E:1676 ||| CC
voriconazole  ||| S:1676 E:1689 ||| NNS
are  ||| S:1689 E:1693 ||| VBP
alternatives ||| S:1693 E:1705 ||| NNS
.  ||| S:1705 E:1707 ||| .
Amphotericin  ||| S:1707 E:1720 ||| NNP
B  ||| S:1720 E:1722 ||| NNP
deoxycholate  ||| S:1722 E:1735 ||| NN
is  ||| S:1735 E:1738 ||| VBZ
not  ||| S:1738 E:1742 ||| RB
recommended  ||| S:1742 E:1754 ||| VBN
for  ||| S:1754 E:1758 ||| IN
any  ||| S:1758 E:1762 ||| DT
indication  ||| S:1762 E:1773 ||| NN
due  ||| S:1773 E:1777 ||| JJ
to  ||| S:1777 E:1780 ||| TO
severe  ||| S:1780 E:1787 ||| JJ
side  ||| S:1787 E:1792 ||| NN
effects ||| S:1792 E:1799 ||| NNS
.  ||| S:1799 E:1801 ||| .
